Nirsevimab
Nirsevimab is a long-acting recombinant human IgG1 kappa monoclonal antibody that provides passive immunization against Respiratory Syncytial Virus (RSV). It works by binding to the prefusion conformation of the RSV fusion (F) glycoprotein, thereby neutralizing the virus and preventing it from entering host cells. Unlike active vaccines, it provides immediate protection, which is particularly beneficial for infants with developing immune systems.
Dosage by Body Weight
Administered as a single intramuscular (IM) injection, preferably in the anterolateral aspect of the thigh. Dosage is based on body weight for infants entering their first RSV season, while a specific dose is designated for vulnerable children entering their second RSV season.
- Body Weight
- Below 5 kg
- Dose
- 50 mg
- Frequency
- Single dose
- Tracking Notes
- Administered as a single intramuscular injection of 50 mg (0.5 mL) for infants entering their first RSV season.
- Body Weight
- 5-7 kg
- Dose
- 100 mg
- Frequency
- Single dose
- Tracking Notes
- Administered as a single intramuscular injection of 100 mg (1 mL) for infants entering their first RSV season.
- Body Weight
- 8-10 kg
- Dose
- 100 mg
- Frequency
- Single dose
- Tracking Notes
- Administered as a single intramuscular injection of 100 mg (1 mL) for infants entering their first RSV season.
- Body Weight
- 11-15 kg
- Dose
- 100 mg (First season) or 200 mg (Second season)
- Frequency
- Single dose
- Tracking Notes
- Infants in their first season receive 100 mg. Eligible high-risk children entering their second RSV season receive 200 mg administered as two separate 100 mg injections at different injection sites.
- Body Weight
- 16-20 kg
- Dose
- 200 mg
- Frequency
- Single dose
- Tracking Notes
- For eligible high-risk children entering their second RSV season. Administered as two separate 100 mg injections at different injection sites.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 50 mg | Single dose | Administered as a single intramuscular injection of 50 mg (0.5 mL) for infants entering their first RSV season. |
| 5-7 kg | 100 mg | Single dose | Administered as a single intramuscular injection of 100 mg (1 mL) for infants entering their first RSV season. |
| 8-10 kg | 100 mg | Single dose | Administered as a single intramuscular injection of 100 mg (1 mL) for infants entering their first RSV season. |
| 11-15 kg | 100 mg (First season) or 200 mg (Second season) | Single dose | Infants in their first season receive 100 mg. Eligible high-risk children entering their second RSV season receive 200 mg administered as two separate 100 mg injections at different injection sites. |
| 16-20 kg | 200 mg | Single dose | For eligible high-risk children entering their second RSV season. Administered as two separate 100 mg injections at different injection sites. |
Formulation
Purpose
Prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Generic Name
NirsevimabBranded Drug Names
Nirsevimab is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.